Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE + icaritin
- Development stage
- Unknown
- Lead developer
- Beijing Shenogen Biomedical
- Modality
- Small Molecules
- Administration
- Oral, Intra-arterial
01
Overview
TACE + acoradine is a combination therapy regimen primarily investigated for the treatment of hepatocellular carcinoma (HCC). It combines Transarterial Chemoembolization (TACE), a locoregional interventional procedure, with acoradine (icaritin), an orally active small molecule. TACE involves the targeted delivery of chemotherapeutic agents (such as doxorubicin or cisplatin) into the tumor's blood supply via the hepatic artery, followed by the administration of embolic agents to induce ischemic necrosis. Acoradine is a prenylated flavonoid derived from the *Epimedium* genus that acts as a first-in-class inhibitor of the estrogen receptor-alpha 36 (ER-α36) variant and modulates the IL-6/JAK/STAT3 signaling pathway to exert immunomodulatory and anti-tumor effects. The combination is designed to leverage the immediate debulking effect of TACE with the sustained systemic activity of acoradine to improve overall survival and reduce recurrence in patients with intermediate or advanced HCC.
- Other names
- TACE + acoradineTACE + SNG1153icaritin + TACETransarterial chemoembolization + icaritin
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)ERα36 (ER-alpha36)DNA
Beyond the preview
Go deeper on TACE + icaritin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE + icaritin.